

Salvatore Lopez

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1295377/salvatore-lopez-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

69

papers

1,416

citations

21

h-index

33

g-index

72

ext. papers

1,775

ext. citations

4.2

avg, IF

4.17

L-index

#	Paper	IF	Citations
69	Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 12238-12243	11.5	123
68	Management of endometrial, ovarian and cervical cancer in the elderly: current approach to a challenging condition. <i>Archives of Gynecology and Obstetrics</i> , 2019 , 299, 299-315	2.5	94
67	The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review. <i>Expert Review of Anticancer Therapy</i> , 2017 , 17, 827-839	3.5	71
66	The Role of Oxidative Stress and Membrane Transport Systems during Endometriosis: A Fresh Look at a Busy Corner. <i>Oxidative Medicine and Cellular Longevity</i> , 2018 , 2018, 7924021	6.7	65
65	Polymerase β (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients. <i>Gynecologic Oncology</i> , 2015 , 138, 11-7	4.9	53
64	Ten years of HPV vaccines: State of art and controversies. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 102, 65-72	7	46
63	T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. <i>Clinical and Experimental Metastasis</i> , 2015 , 32, 29-38	4.7	39
62	Polymerase β (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. <i>Gynecologic Oncology</i> , 2017 , 144, 146-152	4.9	38
61	HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor. <i>Gynecologic Oncology</i> , 2013 , 131, 753-8	4.9	31
60	T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo. <i>Cancer Medicine</i> , 2014 , 3, 1256-65	4.8	30
59	SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1900-9	6.1	29
58	Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo. <i>Gynecologic Oncology</i> , 2014 , 135, 312-7	4.9	29
57	Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 619-624	11.5	28
56	PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas. <i>British Journal of Cancer</i> , 2015 , 113, 1020-6	8.7	27
55	Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 22730-22736	11.5	26
54	Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2). <i>American Journal of Obstetrics and Gynecology</i> , 2013 , 209, 465.e1-9	6.4	25
53	Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 323-333	6.1	24

52	Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2519-26	6.1	24
51	Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. <i>British Journal of Cancer</i> , 2016 , 115, 303-11	8.7	23
50	Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	23
49	Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo. <i>Gynecologic Oncology</i> , 2014 , 135, 142-8	4.9	22
48	Prevalence and role of HER2 mutations in cancer. <i>Pharmacology & Therapeutics</i> , 2019 , 199, 188-196	13.9	21
47	Clostridium perfringens enterotoxin C-terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy-resistant ovarian cancer. <i>International Journal of Cancer</i> , 2015 , 137, 2618-29	7.5	21
46	Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas. <i>Oncotarget</i> , 2020 , 11, 560-570	3.3	21
45	Further insight into prognostic factors in endometrial cancer: the new serum biomarker HE4. <i>Expert Review of Anticancer Therapy</i> , 2017 , 17, 9-18	3.5	19
44	Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo. <i>Gynecologic Oncology</i> , 2015 , 139, 112-7	4.9	19
43	A Predictive Score for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer (SeC-Score): A Single-Centre, Controlled Study for Preoperative Patient Selection. <i>Annals of Surgical Oncology</i> , 2015 , 22, 4217-23	3.1	19
42	Survival outcomes in endometrial cancer patients having lymphadenectomy, sentinel node mapping followed by lymphadectomy and sentinel node mapping alone: Long-term results of a propensity-matched analysis. <i>Gynecologic Oncology</i> , 2020 , 158, 77-83	4.9	19
41	Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. <i>Scientific Reports</i> , 2020 , 10, 973	4.9	19
40	Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015 , 34, 123	12.8	19
39	Ovarian cancer relapse: From the latest scientific evidence to the best practice. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 140, 28-38	7	18
38	PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib. <i>Gynecologic Oncology</i> , 2019 , 155, 144-150	4.9	17
37	Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 118	5.3	17
36	Clostridium perfringens enterotoxin (CPE) and CPE-binding domain (c-CPE) for the detection and treatment of gynecologic cancers. <i>Toxins</i> , 2015 , 7, 1116-25	4.9	17
35	Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo. <i>Cancer</i> , 2015 , 121, 403-12	6.4	16

34	Gynecologic oncology at the time of COVID-19 outbreak. <i>Journal of Gynecologic Oncology</i> , 2020 , 31, e72-4		16
33	Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo. <i>Medical Oncology</i> , 2017 , 34, 91	3-7	14
32	Hormone replacement therapy in cancer survivors: Utopia?. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 124, 51-60	7	14
31	Role of paroxetine in the management of hot flashes in gynecological cancer survivors: Results of the first randomized single-center controlled trial. <i>Gynecologic Oncology</i> , 2016 , 143, 584-588	4-9	14
30	Mechanisms of resistance to HER2-targeted therapies in HER2-amplified uterine serous carcinoma, and strategies to overcome it. <i>Discovery Medicine</i> , 2018 , 26, 39-50	2-5	14
29	Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro. <i>American Journal of Obstetrics and Gynecology</i> , 2016 , 214, 99.e1-8	6-4	13
28	Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo. <i>Molecular Oncology</i> , 2020 , 14, 645-656	7-9	13
27	Adjuvant chemotherapy vs. observation in stage I clear cell ovarian carcinoma: A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2020 , 157, 293-298	4-9	12
26	Uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2021 , 162, 226-234	4-9	12
25	Antiangiogenics and immunotherapies in cervical cancer: an update and future view. <i>Medical Oncology</i> , 2017 , 34, 115	3-7	11
24	Patients treated with neoadjuvant chemotherapy + radical surgery + adjuvant chemotherapy in locally advanced cervical cancer: long-term outcomes, survival and prognostic factors in a single-center 10-year follow-up. <i>Medical Oncology</i> , 2016 , 33, 110	3-7	11
23	The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2017 , 27, 696-702	3-5	10
22	Validation of REM score to predict endometrial cancer in patients with ultrasound endometrial abnormalities: results of a new independent dataset. <i>Medical Oncology</i> , 2017 , 34, 82	3-7	10
21	Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups. <i>Journal of Gynecologic Oncology</i> , 2020 , 31, e92	4	10
20	In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2020 , 156, 430-438	4-9	10
19	Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 4845-4853	12-9	10
18	Novel targeted therapies in ovarian and uterine carcinosarcomas. <i>Discovery Medicine</i> , 2018 , 25, 309-319	2-5	10
17	Role of human epididymis protein 4 (HE4) in detecting recurrence in CA125 negative ovarian cancer patients. <i>International Journal of Gynecological Cancer</i> , 2019 ,	3-5	9

16	PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers. <i>Gynecologic Oncology</i> , 2019 , 153, 158-164	4.9	9
15	Preeclampsia and the challenge of early prediction: reality or utopia? State of art and critical review of literature. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2020 , 33, 677-686	2	8
14	Age-specific predictors of cervical dysplasia recurrence after primary conization: analysis of 3,212 women. <i>Journal of Gynecologic Oncology</i> , 2020 , 31, e60	4	6
13	From the Infection to the Immunotherapy in Cervical Cancer: Can We Stop the Natural Course of the Disease?. <i>Vaccines</i> , 2020 , 8,	5.3	6
12	Implementing the Risk of Endometrial Malignancy Algorithm (REM) adding obesity as a predictive factor: Results of REM-B in a single-center survey. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018 , 225, 51-56	2.4	5
11	May intraperitoneal irrigation with Betadine improve cesarean delivery outcomes? Results of a 6 yearsTsingl centre experience. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2018 , 31, 670-676	2	5
10	Transmission of SARS-CoV-2 in Surgical Smoke during Laparoscopy: A Prospective, Proof-of-concept Study. <i>Journal of Minimally Invasive Gynecology</i> , 2021 , 28, 1519-1525	2.2	5
9	Assessing HPV vaccination perceptions with online social media in Italy. <i>International Journal of Gynecological Cancer</i> , 2019 , 29, 453-458	3.5	4
8	Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro. <i>Tumor Biology</i> , 2015 , 36, 5505-13	2.9	4
7	Anterior colporrhaphy plus inside-out tension-free vaginal tape for associated stress urinary incontinence and cystocele: 10-year follow up results. <i>Neurourology and Urodynamics</i> , 2018 , 37, 1144-1151 ^{2,3}		1
6	Management of gynecological cancer in pregnant patients. <i>Minerva Ginecologica</i> , 2019 , 71, 133-145	1.2	1
5	Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e17028-e17028	2.2	1
4	Undescended or absent ovary without uterine anomalies: systematic review and a single centerT experience. <i>Minerva Obstetrics and Gynecology</i> , 2017 , 69, 35-40		1
3	Postpartum perineal pain: may the vaginal treatment with CO laser play a key-role in this challenging issue?. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2021 , 34, 1190-1197	2	1
2	The role of macroplastique implantation in the management of occult urinary stress incontinence. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018 , 225, 124-128	2.4	
1	Mutational landscape of uterine and ovarian carcinosarcomas.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5589-5589	2.2	